Christopher Klein Net Worth

Christopher Klein biography

Christopher Klein serves as General Counsel, Secretary of the Company. Mr. Klein previously served as the General Counsel of Fougera Pharmaceuticals Inc. from August 2011 to September 2012. Prior to his time at Fougera Pharmaceuticals Inc., Mr. Klein spent six years with King Pharmaceuticals, Inc. where he held the position of Deputy General Counsel prior to King Pharmaceuticals, Inc.'s acquisition by Pfizer, Inc. Prior to that, Mr. Klein spent six years in senior legal roles with Bristol-Myers Squibb Company. Mr. Klein holds a B.A. in Biology from Adelphi University, an M.A. in Education from Columbia University and a J.D. from Fordham University.

What is the salary of Christopher Klein?

As the General Counsel i Secretary of Osmotica Pharmaceuticals Plc, the total compensation of Christopher Klein at Osmotica Pharmaceuticals Plc is $1,511,100. There are 1 executives at Osmotica Pharmaceuticals Plc getting paid more, with Brian Markison having the highest compensation of $4,338,620.

How old is Christopher Klein?

Christopher Klein is 56, he's been the General Counsel i Secretary of Osmotica Pharmaceuticals Plc since 2013. There are 9 older and 7 younger executives at Osmotica Pharmaceuticals Plc. The oldest executive at Osmotica Pharmaceuticals Plc is Fred Weiss, 78, who is the Independent Director.

What's Christopher Klein's mailing address?

Christopher's mailing address filed with the SEC is C/O OSMOTICA PHARMACEUTICALS PLC, 400 CROSSING BOULEVARD, BRIDGEWATER, NJ, 08807.

Insiders trading at Osmotica Pharmaceuticals Plc

Over the last 6 years, insiders at Osmotica Pharmaceuticals Plc have traded over $0 worth of Osmotica Pharmaceuticals Plc stock and bought 6,343,800 units worth $31,350,366 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman oraz Ltd Orbit Co Invest A 1 Llc.... On average, Osmotica Pharmaceuticals Plc executives and independent directors trade stock every 117 days with the average trade being worth of $1,173,603. The most recent stock trade was executed by James Schaub on 16 December 2021, trading 93,800 units of OSMT stock currently worth $100,366.

What does Osmotica Pharmaceuticals Plc do?

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.

Osmotica Pharmaceuticals Plc executives and stock owners

Osmotica Pharmaceuticals Plc executives and other stock owners filed with the SEC include:

• Brian Markison,
  Chairman of the Board, Chief Executive Officer
• Christopher Klein,
  General Counsel, Secretary
• Tina deVries,
  Executive Vice President - Research & Development
• James Schaub,
  Chief Operating Officer, Executive Vice President
• Brian A. Markison,
  Chairman, Pres & CEO
• Christopher A. Klein,
  Gen. Counsel & Sec.
• James D. Schaub,
  Exec. VP & COO
• Dr. Tina Marie deVries,
  Exec. VP of R&D
• Andrew Einhorn,
  Chief Financial Officer
• Fred Weiss,
  Independent Director
• Gregory Cowan,
  Independent Director
• David Burgstahler,
  Director
• Sriram Venkataraman,
  Director
• Juan Vergez,
  Director
• Michael DeBiasi,
  Independent Director
• Lisa Wilson,
  IR Contact Officer
• Joachim Benes,
  Director
• Andrew J. Einhorn CPA,
  Chief Financial Officer
• Jarret Miller,
  Exec. VP of HR
• Sergio Alegre,
  VP of Global Compliance
• Capital Partners Iii Gp, L....,
  
• Ltd Orbit Co Invest A 1 Llc...,
  
• Foundation Harsaul,
  10% owner
• Capital Partners Iii Gp, L....,